07 May JAMA: Substituting Olive Oil for Margarine or Mayo May Reduce Risk of Dementia
Posted at 20:19h
in Alzheimer's - Dementia, Author Interviews, Brigham & Women's - Harvard, JAMA, Nutrition
MedicalResearch.com Interview with:
[caption id="attachment_61650" align="alignleft" width="200"]
Dr. Guasch-Ferré[/caption]
Marta Guasch-Ferré, PhD
Associate Professor and Deputy Head of Section, Section of Epidemiology
University of Copenhagen
Group Leader, Novo Nordisk Foundation Center for Basic Metabolic Research
Adjunct Associate Professor, Department of Nutrition
Harvard TH Chan School of Public Health
MedicalResearch.com: What is the background for this study?
Response: Olive oil is rich in monounsaturated fats and contains compounds with antioxidant activity that may play a protective role for the brain. Olive oil as part of a Mediterranean diet appears to have a beneficial effect against cognitive decline. Higher olive oil intake was previously associated with a lower risk of cardiovascular disease and mortality. But its association with dementia mortality was unknown.
Prof. Mainelis[/caption]
Gediminas "Gedi" Mainelis, Ph.D.
Professor, Department of Environmental Sciences
School of Environmental and Biological Sciences
Rutgers, The State University of New Jersey
MedicalResearch.com: What is the background for this study? What types of particles, ie where do they come from?
Response: This work is a continuation of my research on nanoparticles in consumer products. We have investigated and published on the release of particles from nano-enabled consumer products, such as cosmetic powders, various sprays and clothing.
In this project, we were interested in potential resuspension of particles once nano-enabled consumer sprays are used. The particles are added into consumer products to provide them certain desired properties, like antimicrobial protection, odor reduction or protection against UV (sunscreen). Once the products are used, the particles are released and we could be exposed to them.
Dr. Li Gan[/caption]
Dr. Li Gan PhD
Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases
Brain and Mind Research Institute
Weill Cornell Medical College
[caption id="attachment_61627" align="alignleft" width="150"]
Amy Kennalley[/caption]
Amy Kennalley, MBS
First Year Medical Student
Department of Medical Education
Geisinger Commonwealth School of Medicine
MedicalResearch.com: What is the background for this study
Response: The legalization of medical marijuana (MMJ) and the number of qualifying conditions are expanding across the USA, emphasizing the need to understand the implications of MMJ dispensary distribution for equitable access. Pennsylvania (PA) legalized MMJ in 2016, with the first dispensary opening its doors in 2018. The state currently recognizes 24 medical conditions for MMJ use, including six for which there is insufficient or no evidence for their efficacy as a treatment. Prior research suggests that there is a link between proximity to dispensaries and overall MMJ use. However, a gap exists in our understanding of how dispensary locations might be associated with the specific qualifying conditions for which individuals receive their certification.
In response to this knowledge gap, our study delved into the medical marijuana dispensary access in PA and explored associations with both MMJ certifications and the community demographics. Utilizing data from the Pennsylvania Department of Health, we investigated how proximity to MMJ dispensaries related to the proportion of individuals certified for MMJ use within a specific area or Zip Code Tabulation Area. Additionally, we analyzed the proportion of certifications for conditions with varying levels of evidence supporting the efficacy of MMJ.
This pioneering study represents the first of its kind in PA, shedding light on the association between MMJ dispensary locations and certifications. Likewise, it is the first in the US to investigate the link between dispensary locations and specific qualifying conditions. By examining these dynamics, we aim to contribute vital insights to inform policy and practice, ensuring equitable access to MMJ treatment for individuals with diverse medical needs.
Dr. Tesi[/caption]
MedicalResearch.com Interview with:
RJ Tesi M.D.
CEO and Founder of

Dr. Solgama[/caption]
Jay P. Solgama
Medical Student
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton PA
MedicalResearch.com: What is the background for this study?
Response: The opioid crisis in the United States continues to escalate, with opioid-related deaths increasing by over 800% since 2000. Prescription opioids, particularly oxycodone, have been a contributor to this crisis, with substantial variations in their distribution observed across different states [1,2,3].
Against this backdrop, the study conducted by researchers from the Geisinger Commonwealth School of Medicine aimed to characterize the distribution of oxycodone across US states from 2000 to 2021. By analyzing data from the Drug Enforcement Administration’s comprehensive Automation of Reports and Consolidated Orders System (ARCOS) and the Centers for Disease Control and Prevention Wide-ranging ONline Data for Epidemiologic Research (WONDER) databases, the study sought to identify trends and patterns in oxycodone distribution and their potential implications for opioid-related deaths [4,5].
Dr. Thomas Robert[/caption]
MedicalResearch.com Interview with:
Thomas Robert, MD, AIX
Associate Professor of Nephrology
APHM (Assistance Publique - Hopitaux de Marseille)
Marseille, Provence-Alpes-Côte d'Azur, France
[caption id="attachment_61498" align="alignleft" width="132"]
Dr. Letavernier[/caption]
Prof. Emmanuel Letavernier, MD PhD
Nephrologist at Tenon Hospital
Paris, France
MedicalResearch.com: What is the background for this study?
Response: Our work was prompted by emerging concerns surrounding the potential nephrotoxic effects of hair-straightening products containing glyoxylic acid. This inquiry was instigated by a patient who experienced three repeated acute episodes of kidney injury in June 2020, April 2021, and July 2022, each occurring shortly after a hair-straightening procedure. Notably, these episodes resolved with hydration.
Upon examining the composition of the hair product used by the patient, which contained glyoxylic acid, and considering the patient's report of painful ulcer scalp during application and subsequent scalp scarring, we suspected a potential link between exposure to glyoxylic acid and kidney injury. Consulting with my colleague, Professor Emmanuel Letavenier, a specialist in crystalline nephropathy at Paris, confirmed this suspicion.
In summer 2023, cases series have been reported by an Israeli team (
Dr. Cortese[/caption]
Marianna Cortese, MD, PhD
Senior Research Scientist